Summary
Machine-generated summaryThe contract covers the supply of a medicinal product whose active substance is palivizumab, a recombinant humanised monoclonal antibody produced by DNA technology in mouse myeloma host cells. One 0.5 ml injection vial contains 50 mg of palivizumab. The product is indicated for the prevention of serious lower respiratory tract disease requiring hospitalisation caused by the respiratory syncytial virus (RSV) in children at high risk: children born at 35 weeks of gestation or earlier who are younger than 6 months at the start of the RSV season; children up to 2 years who required treatment for bronchopulmonary dysplasia within the last 6 months; and children up to 2 years with haemodynamically significant congenital heart disease.
Description
Official source
Source: TED - Tenders Electronic Daily (Publications Office of the EU)
Always verify details on the official notice.
Last verified against TED - Tenders Electronic Daily (Publications Office of the EU) 12 hours ago
More from this buyer
Full buyer profileThis buyer has no award history in this sector yet. Usual winners, Medical equipment & pharmaceuticals - Slovakia
| Company | Wins | Total awarded | Last win |
|---|---|---|---|
| BIOTECH s.r.o. | 42 | €195,457 | Aug 2026 |
| ProScience Tech s. r. o. | 20 | €62,217 | Sep 2026 |
| LABO - SK, s. r. o. | 14 | €34,918 | Sep 2026 |
| Surgitech s. r. o. | 13 | €2.4M | Aug 2026 |
| UNIPHARMA - 1. slovenská lekárnická akciová spoločnosť | 11 | €1.1M | Sep 2026 |
Based on 391 awards with a linked company profile over the last 2 years.
Similar tenders
5
days left
€251,287
est. value
6
days left
€5,750,000
est. value
7
days left
€18,343
est. value
Market context
- Avg. open tender · Medical equipment & pharmaceuticals
- €10,113,906
- Buyer track record on Aperlena
- 10 notices tracked · 3 awarded
Never miss a tender like this
25 new notices in Medical equipment & pharmaceuticals in Slovakia in the last 7 days. Get an email when new ones appear. Free.
Set up my alert